Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CFTR | P13569 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524336 | 0.94 | MAPT (0.43) | HPGDALDH1A1CFTRMAPTADORA3 | |
| SCHEMBL1523610 | 0.92 | CFTR (0.39) | MAP3K5HPGDALDH1A1CFTRMAPT | |
| SCHEMBL1523711 | 0.91 | MAP3K5 (0.40) | MAP3K5HPGDALDH1A1CFTRMAPT | |
| SCHEMBL1523845 | 0.89 | CFTR (0.38) | MAP3K5HPGDALDH1A1CFTRMAPT | |
| SCHEMBL1523773 | 0.89 | MAPT (0.42) | MAP3K5HPGDALDH1A1CFTRMAPT | |
| SCHEMBL1523660 | 0.88 | MEN1 (0.47) | MAP3K5HPGDALDH1A1MAPTADORA3 | |
| SCHEMBL1523748 | 0.85 | GRM5 (0.45) | ALDH1A1MAPTADORA3KDM4EHSD17B10 | |
| SCHEMBL1523955 | 0.85 | MAP3K5 (0.43) | MAP3K5GSK3BDYRK1AMEN1KMT2A | |
| SCHEMBL1523798 | 0.84 | MAP3K5 (0.47) | MAP3K5GSK3BDYRK1AMEN1KMT2A | |
| SCHEMBL1523646 | 0.84 | MAP3K5 (0.42) | MAP3K5GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | MAP3K5 11/4885HPGD 2241/4885ALDH1A1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.